Skip to main content
. 2011 Jun 16;118(7):1877–1884. doi: 10.1182/blood-2011-03-343145

Table 1.

In vitro cytotoxicity of nAb-IFNα on hematopoietic tumor cell lines

Cell line Type HLA-DR expression, MFI CD20 expression, MFI C2-2b-2b
20-2b-2b
734-2b-2b
hL243γ4p
hL243γ4p + 734-2b-2b
IC50, nM TI, fold Imax, % IC50, nM TI, fold Imax, % IC50, nM Imax, % IC50, nM Imax, % IC50, nM Imax, %
Daudi BL 2092* 500* 3 × 10−5 117 95 1 × 10−4 25 95 3 × 10−3 95 5.13 67 4 × 10−3 95
Raji BL 2317* 391* 0.35 23 70 3.89 2 60 8.13 62 > 20 45 0.56 70
Ramos BL 373* 516* 0.90 > 20 82 7.76 > 3 70 > 20 35 > 20 25 > 20 43
WSU-FSCCL FL 2030* 37* 0.19 > 100 80 > 20 22 > 20 24 0.37 85 0.46 73
Jeko-1 MCL 539* 250* 0.10 > 200 100 1.1 > 20 59 > 20 21 0.4 98 0.18 90
Granta-519 MCL 1797* 805* 4.0 > 5 66 > 20 31 > 20 14 6.4 59 3.5 66
CAG MM 2804* 4* 3 × 10−3 55 98 0.13 1 85 0.16 85 20 52 0.08 98
NCI-H929 MM 4 1 0.13 1 98 0.14 1 98 0.11 98 > 20 0 0.12 98
KMS12-PE MM 940* 3* 0.63 6 80 3.28 1 72 3.9 68 > 20 27 0.97 76
KMS12-BM MM 1502* 318* 0.51 > 50 73 7.82 > 3 55 > 20 22 3.47 59 0.61 73
MM1R MM 79 1 2 × 10−3 10 100 0.05 0.5 95 0.02 97 > 20 10 0.03 98
KMS11 MM 615* 3* 1.85 > 10 66 > 20 21 > 20 24 2.19 62 1.72 66
OPM6 MM 41 2 4 × 10−3 2 99 8 × 10−3 1 99 8 × 10−3 99 > 20 6 8 × 10−3 99
U266 MM 223 2 9 × 10−4 22 96 0.02 1 93 0.02 92 > 20 10 8 × 10−3 91
HC-1 HCL 5501* 1079* 0.08 134 91 0.47 23 69 10.72 59 0.59 89 0.49 89
Kasumi-3 AML 445* 5* 6 × 10−3 18 87 0.10 1 78 0.11 76 > 20 0 0.09 81
GDM-1 AML 553* 4* 8 > 3 68 > 20 11 > 20 35 > 20 0 > 20 35
MEC-1 CLL 2421* 271* 1.2 17 78 20 > 1 50 > 20 34 > 20 30 20 50
WAC CLL 799* 211* 2.19 > 10 79 > 20 26 > 20 20 > 20 37 5.89 60
REH ALL 2583* 15* 2.14 12 67 13.80 2 57 26.30 52 7.46 64 4.95 64
697 ALL 1108* 13* > 20 40 > 20 40 > 20 23 > 20 18 > 20 34
RS4/11 ALL 2522* 3* > 20 41 > 20 39 > 20 36 > 20 19 > 20 41

Cultures were grown in 48-well plates until the density of untreated cells increased a minimum of 10-fold (3-7 days).

MFI indicates mean fluorescent intensity; IC50, concentration (nM) resulting in 50% growth inhibition compared with untreated cells; TI, targeting index = fold reduction in EC50 compared with nontargeted IFNα (734-2b-2b); Imax, maximal percentage decrease in viable cells compared with untreated cells; BL, Burkitt lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MM, multiple myeloma; HCL, hairy cell leukemia; AML, acute myeloid leukemia; CLL, chronic lymphoid leukemia; and ALL, acute lymphoblastic leukemia.

*

Previously reported in Rossi et al.15

Treatment failed to reach 50% inhibition.

Previously reported in Rossi et al.14